TKI Toxicity — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Dose reduction of lenvatinib (20 mg → 14 mg → 10 mg daily)
Diarrhoea is one of the most common TKI class-effect adverse events (distinct from immune-related diarrhoea). Management of TKI-associated diarrhoea focuses on antidiarrhoeal agents (loperamide), dietary modification, and stepwise dose reduction if grade ≥2 persists. Lenvatinib dose modifications follow the 20 mg → 14 mg → 10 mg reduction scheme. Infliximab and systemic corticosteroids are NOT appropriate for TKI-induced diarrhoea (they address immune-mediated, not direct drug-effect diarrhoea). Treatment interruption with dose reduction is key.
Reference: BNF Lenvatinib monograph; NICE TA535 Lenvatinib; ESMO 2024 Supportive Care Guidelines